The project was also financed in part by the Commonwealth of Pennsylvania and department of community and economic development through the funding to Ben Franklin Technology Partners of Southeastern PA.
The funding forms part of Match for Sponsored Research Program (SRA), which adds to the $125,000 Sponsored Research Agreement executed between Eqalix and Temple University.
Eqalix chairman and CEO Joseph Connell said the company is excited to receive the financial support of NTI to advance the development of OmegaSkin.
"OmegaSkin has the potential to heal full thickness wounds without scarring and has the potential to change the way we treat chronic wounds, burns and accelerate the physiologic healing in aesthetic dermatology applications," Connell added.